Zai Lab Limited (ZLAB)

NGM – Real vaqt narxi. Valyuta: USD

19.53

-0.06 (-0.31%)

Yopilishda: May 12, 2026, 4:00 PM EDT

19.69

+0.16 (0.82%)

Bozordan keyin: May 12, 2026, 7:56 PM EDT

Kompaniya haqida

Zai Lab Limited, bir biopharmaceutical kompaniyasi, onkologiya, immunologiya, nevrologiya va yuqumli kasalliklar sohalaridagi tibbiy sharoitlarga mo'ljallangan mahsulotlarni kashf qilish, ishlab chiqish va tijoratlashtirishga qaratilgan. Uning tijoriy mahsulotlari orasida tuxumdon rakini davolash uchun og'iz orqali yuboriladigan poli (ADP-riboza) polimeraza 1/2 ingibitori bo'lgan Zejula; generalizatsiya qilingan miyasteniya gravis va surunkali yallig'lanishli demiyelinizatsiya qiluvchi polineyropatiyani davolash uchun inson IgG1 antitel fragmenti bo'lgan VYVGART; hamjamiyatda orttirilgan bakterial pnevmoniya va teri va teri tuzilmalarining o'tkir bakterial infektsiyalari uchun NUZYRA; glialastoma uchun Optune; oshqozon-ichak stromal o'smalari uchun Qinlock; Acinetobacter baumannii-calcoaceticus kompleksi tomonidan qo'zg'atilgan kasalxonada orttirilgan va ventilyator bilan bog'liq bakterial pnevmoniyani davolash uchun Xacduro; va ROS proto-onkogen 1 va mayda hujayrali bo'lmagan o'pka rakini davolash uchun Augtyro mavjud. Kompaniya Tesaro, Inc., NovoCure Ltd., Deciphera Pharmaceuticals, LLC, Paratek Bermuda Ltd., argent BV, Turning Point Therapeutics, Inc., Entasis Therapeutics Holdings Inc., Karuna Therapeutics, Inc., Pfizer Inc., Amgen Inc. va Boehringer Ingelheim GmbH bilan strategik hamkorlikni amalga oshiradi. Kompaniya 2013-yilda tashkil etilgan va Xitoyning Pudong shahrida joylashgan.

Asosiy rahbarlar

Ism	Lavozim
Dr. James Yan DABT, M.D., Ph.D.	Chief Operating Officer of R&D
Dr. Rafael G. Amado M.D.	President and Head of Global Research & Development
Dr. Shan He Ph.D.	Senior VP & Chief Business Officer
Dr. Yajing Chen Ph.D.	Chief Financial Officer
Dr. Ying Du Ph.D.	Founder, Chairperson & CEO
Mr. Frazor Titus Edmondson III, J.D.	Chief Legal Officer & Corporate Secretary